Pure Global

Formosa Plastics Biomedical Novel Coronavirus Antigen Rapid Test Reagent for Home Use - Taiwan Registration 16bc3e61b1c7317438e914f5e140f408

Access comprehensive regulatory information for Formosa Plastics Biomedical Novel Coronavirus Antigen Rapid Test Reagent for Home Use in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 3 medical device is registered under number 16bc3e61b1c7317438e914f5e140f408 and manufactured by Formosa Biomedical Technology Co., Ltd. Yilan Factory. The authorized representative in Taiwan is Formosa Biomedical Technology Co., Ltd. Yilan Factory.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
89,000+ Devices
16bc3e61b1c7317438e914f5e140f408
Registration Details
Taiwan FDA Registration: 16bc3e61b1c7317438e914f5e140f408
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Formosa Plastics Biomedical Novel Coronavirus Antigen Rapid Test Reagent for Home Use
TW: ๅฐๅก‘็”Ÿ้†ซๅฎถ็”จๆ–ฐๅž‹ๅ† ็‹€็—…ๆฏ’ๆŠ—ๅŽŸๅฟซ้€Ÿๆชข้ฉ—่ฉฆๅŠ‘
Risk Class 3

Registration Details

16bc3e61b1c7317438e914f5e140f408

Company Information

Product Details

This product is used to qualitatively detect the nucleoprotein of the novel coronavirus in the nasal cavity of patients with suspected symptoms of novel coronavirus pneumonia (COVID-19) in the acute infection stage with suspected symptoms of novel coronavirus pneumonia (COVID-19). A positive result cannot rule out bacterial infection or co-infection with other viruses, and a negative result cannot completely rule out novel coronavirus pneumonia infection, and this product alone should not be used as the sole basis for treatment or management decisions including infection control.

B Hematology, pathology, and genetics

B.4020 Analysis of specific tests

ๅœ‹็”ข;; QMS/QSD

Dates and Status

Dec 18, 2023

Dec 18, 2028